News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

IntelligentMDx to Present CE-Marked Flu A/B and RSV Assay at ECCMID

4/25/2013 12:12:25 PM

April 25, 2013 -- IntelligentMDx (IMDx) will be presenting design and development of a recently CE-marked automated test for detection and differentiation of Influenza A, Influenza B, and Respiratory Syncytial Virus (RSV) at the 23rd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) Meeting being held on April 27 - 30, 2013 in Berlin, Germany. The ECCMID meeting is an international forum for infectious disease specialists to gather for updates and discussions on emerging infections, diagnosis, prevention, and treatment.

The IMDx Flu A/B and RSV for Abbott m2000 assay will be presented by Dr. Heinz Reiske, Assay Development Manager at IMDx, during the Viral Infections poster session. The poster will detail the technology used in assay development as well as performance characteristics.

To view this poster at ECCMID, please visit:

Tuesday, April 30, 2013, Viral Infections Poster Session, 12:30 – 13:30

Development and Performance of a High-Throughput Assay for Detection of Influenza A, Influenza B, and Respiratory Syncytial Virus (RSV) for use on the Abbott m2000

H. Reiske*, P. Labrousse, S. Bradley, C. Leslin, A. Nesselrodt (Cambridge, US)

In addition to the Flu A/B and RSV assay, the IMDx portfolio of infectious disease diagnostics includes CE-marked tests for toxigenic Clostridium difficile, Vancomycin-Resistant Enterococci, Herpes Simplex Viruses 1 & 2, and Group B Streptococcus.

* The IMDx Flu A/B and RSV assay is CE-marked and not available for sale in the United States.

About IMDx

Based in Cambridge, MA, IMDx ( is an innovator of unique proprietary molecular tests equipped with features and benefits to port onto nearly any molecular testing system. IMDx’s competitive advantage lies in its extensive bioinformatics capabilities, enabling the production of rapid, low cost high quality products with top performance characteristics to empower clinicians to provide care with greater certainty. Current and future product lines include tests for Infectious Diseases (Healthcare Associated Infections, respiratory diseases, STDs, prenatal testing), oncology and other human genetic targets. The IMDx facilities are ISO 13485:2003 certified and all of the IMDx products are developed and manufactured within a regulatory compliant (FDA QSR, CE-IVDD and cGMP) environment.

Renda Hawwa, Ph.D.

Business Development Analyst


19 Blackstone Street

Cambridge, MA 02139

Phone: (617) 871-6405

Fax: 617-871-6399


Visit us at

Read at

comments powered by Disqus